pms-Erlotinib Special Precautions

pms-ERLOTINIB should be prescribed and managed only by a doctor who is experienced with anticancer drugs.
The patient must have a confirmed activating mutation of the EGFR-TK prior to starting of first-line pms-ERLOTINIB monotherapy.
Erlotinib has not been studied in patients with severely reduced liver function.
Erlotinib has not been studied in patients with severely reduced kidney function.
Serious side effects that have been reported with erlotinib include: liver failure, including fatal cases; gastrointestinal perforation (a hole through the wall of the stomach or small intestine, or large bowel), including fatal cases.
Before using pms-ERLOTINIB, talk to the doctor or pharmacist if: there are liver problems; there are kidney problems; there are gastrointestinal ulcers (bleeding of the stomach or intestines) or diverticular disease; there are cataracts, there had been cataract surgery, or wearing contact lenses; there is lung disease; smoking tobacco; planning to become pregnant; planning to breastfeed; told by the doctor that some sugars cannot be tolerated.
Smoking tobacco may reduce pms-ERLOTINIB blood level.